Leronlimab (anti-CCR5) is a humanized monoclonal antibody to CCR5, blocks breast cancer cellular metastasis and enhances cell death induced by DNA damaging chemotherapy. It is being investigated as a potential therapy in the treatment of HIV infection.In vitroLeronlimab binds CCR5 in multiple breast cancer cell lines, reducing ligand-induced Ca2+ signaling, invasion of TNBC into Matrigel, and transwell migration, also enhances the breast cancer (BCa) cell killing of the BCa chemotherapy reagent, doxorubicin.In vivoIn xenografts conducted with Nu/Nu mice, leronlimab reduces lung metastasis of the TNBC cell line, MB-MDA-231, reducing the metastatic tumor burden of established TNBC lung metastasis. Purity>95% (SDS-PAGE&SEC)Endotoxin Level< 1.0EU/mg. Specification: ExactAb™, Validated, Carrier Free, Low Endotoxin, Azide Free, Recombinant, ≥95%(SDS-PAGE&SEC), Lot by Lot
- UPC:
- 12352203
- Condition:
- New
- Availability:
- 8-12 weeks
- Weight:
- 1.09 Ounces
- HazmatClass:
- No
- WeightUOM:
- LB
- MPN:
- Ab169252-1mg
- CAS:
- 674782-26-4
- Product Size:
- 1mg
